DEC 25, 2019 8:27 AM PST

New Drug to Make Breast Cancer Treatment More Affordable

WRITTEN BY: Annie Lennon

The US Food and Drug Administration has granted accelerated approval to new breast cancer drug, trastuzumab deruxtecan. The drug’s increasing recognition, including a prequalification status from the World Health Organization, could make the breast cancer treatment significantly cheaper, and thus more accessible, to women worldwide. 

A biosimilar version of existing treatment, Trastuzumab (meaning it is made from living organisms rather than synthetic chemicals yet has similar clinical effects), it is available at just 35% of the cost of the original drug- currently costing $20,000. And now, its prequalification status from the WHO means that its price is expected to decrease even further. 

This is great news for women around the world, particularly those in developing nations where conventional drugs are too expensive. Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said, “Women in many cultures suffer from gender disparity when it comes to accessing health services. In poor countries, there is the added burden of a lack of access to treatment for many, and the high cost of medicines. Effective, affordable breast cancer treatment should be a right for all women, not the privilege of a few.”

In particular, this new drug works against HER2-positive breast cancer, a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), known to stimulate the growth of cancer cells. Responsable for around 20% of cases of breast cancer, it is caused by a gene mutation that makes excess HER2 proteins. 

From its phase 2 trial, researchers found that the drug was generally effective in treating women with this strain of breast cancer, even when it had already spread to other parts of the body. In their study of 184 women already treated with two or more ati-HER2 therapies including trastuzumab, trastuzumab emtansine and pertuzumab, they found that 60.3% of the women responded positively to the drug. 

One of the study’s researchers, Ian Krop MD said, “Those (results) are roughly double or triple what we've typically seen in other studies of this third- and later-line (treatment) population, where the median progression-free survival has been in the 4- to 5-month range.”

Despite the drug’s promise however, researchers have warned that it comes with side effects including potentially fatal interstitial lung disease and pneumonitis. In particular, they warn patients and physicians alike to be vigilant for symptoms such as coughing, dyspnea, fever and worsening respiratory health and that, should they notice any of them, to cease treatment immediately.  

 

Sources: Mayo Clinic, Medscape, World Health Organization and Cancer Network 

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
APR 18, 2020
Cancer
APR 18, 2020
A New Double Threat Against Skin Cancer
Skin cancer is one of the most common cancers in America.  One of the most aggressive forms of cancer is melanoma, ...
MAY 04, 2020
Immunology
MAY 04, 2020
GeoVax and Sino Bio Collaborate on COVID-19 Vaccine Work
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ...
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
MAY 19, 2020
Drug Discovery & Development
MAY 19, 2020
COVID-19 Vaccine On Track for Late 2020
Moderna, a biotechnology company based in Massachusetts, has released information on its vaccine against COVID-19 from i ...
MAY 23, 2020
Cancer
MAY 23, 2020
A New Biomarker to Identify a Triple Negative Breast Cancer Prognosis
Breast cancer, one of the most common cancers in the world, are commonly separated into one of several sub-types. These ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Drug Targets Off Episodes of Parkinson
A novel drug was approved by the FDA to target the “off” episodes of Parkinson disease. The drug is referred ...
Loading Comments...